During R&D for a new bioprocess, a developer wants to know as much as possible about any therapeutic candidate. When it comes to monoclonal antibody (mAb)-based biotherapeutics, a bioprocessor wants to understand a mAb’s features. At Abveris, a contract research organization for monoclonal-antibody discovery, COO Tracey Mullen says that one way they do that is by using the Beacon Optofluidic Platform from Berkeley Lights. With this platform, Mullen says, Abveris can “perform accelerated discovery of biologics-based therapeutic drug candidates through the use of high-resolution, multifactorial interrogation of antibodies secreted from individual plasma B cells.”
